Michael Ferguson

Professor

Dundee University

Mike studies the biochemistry of protozoan parasites. With colleagues, he established the Drug Discovery Unit at the University of Dundee in 2006, which has resulted in compounds in Phase 1 and 2 clinical trials and the generation of spin-out companies. Mike is also co-Director of the Dundee Proteomics Facility, one of the largest in Europe, that accelerates discovery and translational science.

 

Mike believes that research should generate new knowledge and provide returns for its key stakeholders: patients and the taxpayer.

 

He was a member and Deputy Chair (2012-2021) of the Wellcome board of governors and is on the boards of the Medicines for Malaria Venture (MMV) and UK Biobank.

Leonid Chindelevitch

Lecturer

Imperial College London

Sofia Corte-Real

CSO

Technophage

Penny Walker-Robertson

Deputy Director, C19 Policy

UK Health Security Agency

Lloyd Payne

CEO

Arrepath

Ghada Zoubiane

Head of Partnerships and Stakeholder Engagement

International Centre for AMR Solutions (ICARS)

Jonathan Pearce

CEO

Antibiotic Research UK

Jasvinder Singh

Head of New Active Substances and Innovative Medicine

MHRA

Glenn Dale

CDO

BioVersys

Remko van Leeuwen

CEO

Madam Therapeutics